Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | FASN | P49327 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.38 |
| ▸ | MGLL | Q99685 | 2/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20555552 | 0.91 | USP2 (0.39) | USP2SMN1; SMN2GPR119MGLLDDB1 | |
| SCHEMBL17324893 | 0.84 | SIGMAR1 (0.45) | USP2SMN1; SMN2GPR119DDB1CRBN | |
| SCHEMBL18418204 | 0.82 | MGLL (0.52) | GPR119MGLLHDAC1HDAC8HDAC6 | |
| SCHEMBL738670 | 0.81 | GPR119 (0.49) | GPR119DDB1CRBN | |
| SCHEMBL15544785 | 0.81 | USP2 (0.40) | USP2SMN1; SMN2GPR119MGLLACACB | |
| SCHEMBL4542010 | 0.81 | USP2 (0.43) | USP2SMN1; SMN2GPR119DDB1CRBN | |
| SCHEMBL10111390 | 0.80 | USP2 (0.41) | USP2SMN1; SMN2GPR119DDB1CRBN | |
| SCHEMBL17317373 | 0.80 | OPRM1 (0.45) | USP2SMN1; SMN2GPR119DDB1CRBN | |
| SCHEMBL4542086 | 0.80 | USP2 (0.40) | USP2SMN1; SMN2FASNGPR119DDB1 | |
| SCHEMBL17324919 | 0.80 | USP2 (0.40) | USP2SMN1; SMN2GPR119DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649248-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2023-05-16 | — | — | US | disclosed |
| US-11649248-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2023-05-16 | — | — | US | disclosed |
| US-11649248-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2023-05-16 | — | — | US | disclosed |
| EP-3377500-B1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | ESTEVE PHARMACEUTICALS SA (ES) | 2022-10-19 | — | — | EP | disclosed |
| US-20210115062-A1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | ESTEVE PHARMACEUTICALS SA (ES) | 2021-04-22 | — | — | US | disclosed |
| US-20210115062-A1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | ESTEVE PHARMACEUTICALS SA (ES) | 2021-04-22 | — | — | US | disclosed |
| US-10927128-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | ESTEVE PHARMACEUTICALS. S.A. (ES) | 2021-02-23 | — | — | US | disclosed |
| US-10927128-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | ESTEVE PHARMACEUTICALS. S.A. (ES) | 2021-02-23 | — | — | US | disclosed |
| EP-3149006-B1 | ALKYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2020-09-09 | — | — | EP | disclosed |
| EP-3149006-B1 | ALKYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2020-09-09 | — | — | EP | disclosed |
| US-20170313723-A1 | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-11-02 | — | — | US | disclosed |
| US-20170313723-A1 | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-11-02 | — | — | US | disclosed |
| EP-2744333-B1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015185209-A1 | ALKYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2015-12-10 | — | — | WO | disclosed |
| US-9084794-B2 | Fatty acid synthase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2015-07-21 | — | — | US | disclosed |
| US-20140194415-A1 | FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline Intellectual Property (No2) Limite (GB) | 2014-07-10 | — | — | US | disclosed |
| EP-2744333-A1 | FATTY ACID SYNTHASE INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2014-06-25 | — | — | EP | disclosed |
| WO-2014008223-A2 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-01-09 | — | — | WO | disclosed |
| WO-2013052716-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-04-11 | — | — | WO | disclosed |
| WO-2013028447-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649248-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | OPRD1, OPRM1, OPRK1 | USP2 2713/4885SMN1; SMN2 3963/4885FASN 1799/4885 |
| US-20140194415-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS2, FADS1 | USP2 3234/4885SMN1; SMN2 4692/4885FASN 1/4885 |
| US-20170313723-A1 | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | OPRD1, SIGMAR1, OPRM1 | USP2 1847/4885SMN1; SMN2 775/4885FASN 2310/4885 |
| US-10927128-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | OPRD1, OPRM1, OPRK1 | USP2 2713/4885SMN1; SMN2 3963/4885FASN 1799/4885 |
| US-20210115062-A1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | OPRD1, OPRM1, OPRK1 | USP2 2725/4885SMN1; SMN2 4000/4885FASN 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.